Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypersensitivity to scopolamine in the elderly.

C Flicker1, S H Ferris, M Serby

  • 1Department of Psychiatry (HN 314), New York University Medical Center, New York 10016.

Psychopharmacology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Positron emission tomography in the study of aging and senile dementia.

Neurobiology of aging·2013
Same author

Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study.

International journal of clinical practice·2013
Same author

Novel white matter tract integrity metrics sensitive to Alzheimer disease progression.

AJNR. American journal of neuroradiology·2013
Same author

Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.

The journal of nutrition, health & aging·2009
Same author

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience.

The journal of nutrition, health & aging·2009
Same author

Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.

Neurology·2009

Scopolamine hydrobromide significantly impacts cognitive function, especially in elderly individuals. While effects are qualitatively similar across age groups, the magnitude is greater in older adults, not modeling Alzheimer's disease.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Scopolamine hydrobromide is a known cognitive impairing agent.
  • Understanding age-related differences in drug response is crucial for pharmacology and gerontology.

Purpose of the Study:

  • To compare the cognitive effects of scopolamine hydrobromide in young and elderly subjects.
  • To assess the dose-dependent effects and qualitative similarities/differences in cognitive impairment.

Main Methods:

  • A double-blind, placebo-controlled study involving 20 subjects (10 young, 10 elderly).
  • Administration of scopolamine hydrobromide (0.43 mg/70 kg) via subcutaneous injection.
  • Assessment using a comprehensive neuropsychological test battery measuring memory, visuospatial praxis, and psychomotor speed.

Related Experiment Videos

Main Results:

  • Scopolamine impaired recent memory and visuospatial praxis in both age groups.
  • Cognitive impairments were quantitatively larger in elderly subjects.
  • Psychomotor slowing was significant in the elderly, requiring higher doses in young subjects.

Conclusions:

  • Cognitive effects of scopolamine are more pronounced in the elderly but qualitatively similar to young adults.
  • Scopolamine's effects in the elderly do not serve as a valid model for Alzheimer's disease cognitive dysfunction.